VIPR2 Antikörper (AA 334-423)
Kurzübersicht für VIPR2 Antikörper (AA 334-423) (ABIN2799766)
Target
Alle VIPR2 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 334-423
-
Verwendungszweck
- VPAC2 antibody, 1 mg/ml
-
Immunogen
- Synthetic peptide corresponding to a region within amino acids 334-423 of VPAC2
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
Tested Western blot
Application Notes
Suggested starting dilutions are as follows: WB: 1:500-1:3000. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.Sample (30 μg of whole cell lysate) A: Hela 10 % SDS PAGE 107-10212 diluted at 1:1000 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 mg/mL
-
Buffer
- 1XPBS, 1 % BSA, 20 % Glycerol ( pH 7). 0.01 % Thimerosal was added as a preservative.
-
Konservierungsmittel
- Thimerosal (Merthiolate)
-
Vorsichtsmaßnahmen
- This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- -20°C
-
-
- VIPR2 (Vasoactive Intestinal Peptide Receptor 2 (VIPR2))
-
Andere Bezeichnung
- VPAC2
-
Molekulargewicht
- 49 kDa
-
Gen-ID
- 7434
-
Pathways
- cAMP Metabolic Process
Target
-